期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
The Characteristic of an Anti-Human DR5 Antibody A6
1
作者 Yugang Wang Kuipeng Zhao +4 位作者 Jugao Chen Jiyan Zhang Ming Yu Yan Li Beifen Shent 《Cellular & Molecular Immunology》 SCIE CAS CSCD 2008年第3期183-188,共6页
The efficacy of many cancer treatments is due to their ability to induce apoptosis. DR5 can activate apoptosis pathway after binding with its natural ligand, tumour necrosis factor-related apoptosis-inducing ligand (... The efficacy of many cancer treatments is due to their ability to induce apoptosis. DR5 can activate apoptosis pathway after binding with its natural ligand, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL/ Apo2L). Both TRAIL and agonistic anti-DR5 monoclonal antibody are currently being explored for cancer therapy. The mechanisms of cytotoxicity of our previously prepared monoclonal antibody A6 against DR5 were investigated here. A6 could cause viability loss of Jurkat cells in both time- and dose-dependent manner which could be attributed to the activation of apoptosis pathway. Caspases 3, 8 and 9 were activated in Jurkat cells and the caspase specific inhibitors, such as broad caspases inhibitor Z-VAD-FMK, caspase 8 specific inhibitor Z-IETDFMK and caspase 9 specific inhibitor Z-LEHD-FMK could recover the viability loss caused by A6. The function and molecular mechanism of TRAIL-mediated apoptosis were also investigated and compared with those of A6. Although A6 and TRAIL recognize a different epitope, they could induce a similar reaction in Jurkat cells. 展开更多
关键词 anti-dr5 antibody A6 APOPTOSIS caspase inhibitor
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部